Clinical

Dataset Information

0

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)


ABSTRACT: This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Cancer,Patients With Ring Finger Protein 43 (rnf43) Or R-spondin (rspo) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer,Colorectal Neoplasms,Pacientes Con Alteración De Ring Finger Protein 43 (rnf43) O De R-spondin (rspo), Metastásico, Con Estabilidad De Microsatélites, Cáncer Colorrectal

PROVIDER: 2379122 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2012-10-04 | E-GEOD-41326 | biostudies-arrayexpress
2012-10-04 | GSE41326 | GEO
2022-11-09 | GSE213453 | GEO
2021-07-19 | ST001902 | MetabolomicsWorkbench
2022-03-23 | GSE188946 | GEO
| 2307948 | ecrin-mdr-crc
2023-12-31 | GSE145948 | GEO
| S-EPMC10603338 | biostudies-literature
| S-EPMC8648784 | biostudies-literature
2023-10-19 | PXD043151 | JPOST Repository